BiotechTube
Keli Therapeutics

Keli Therapeutics

Berlin, Europe - Other· Est.
keli.eu
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

KELI Therapeutics is a private, pre-revenue biotech founded in 2017 and headquartered in Kaunas, Lithuania, with a presence in Berlin. The company is developing a diversified pipeline of autologous and allogeneic cell therapies, primarily for cartilage repair and inflammatory diseases, with its lead programs in pre-clinical and early clinical development. It recently secured a €2.5 million grant from the European Innovation Council to fund a clinical trial in Acute Kidney Injury, indicating external validation and non-dilutive funding. Leadership comprises experienced professionals in regenerative medicine, manufacturing, and clinical development.

OrthopedicsNephrologyInflammatory DiseasesDermatology

Technology Platform

Autologous chondrocyte technology for cartilage repair; Allogeneic immunomodulatory stem cell platform for inflammatory diseases; Exosome (extracellular vesicle) and tissue-derived product technologies.

Opportunities

The €2.5 million EIC grant provides non-dilutive funding to generate clinical proof-of-concept in Acute Kidney Injury, a high-unmet-need area with no approved disease-modifying therapies.
The company's multi-platform approach (autologous, allogeneic, exosomes) allows for expansion into large, adjacent markets like dermatology, wellness, and other inflammatory diseases beyond its initial orthopedic focus.

Risk Factors

As an early-stage biotech, KELI faces significant clinical development and regulatory approval risks for its novel cell therapies.
Manufacturing and scaling complex autologous and allogeneic products cost-effectively presents a major operational challenge.
The company operates in highly competitive spaces (orthobiologics, cell therapy) and will need to differentiate its products to achieve commercial success.

Competitive Landscape

In orthopedics, KELI competes with other cell therapy companies (e.g., Kolon TissueGene, Vericel), platelet-rich plasma (PRP) providers, and established surgical procedures. In the broader cell and exosome therapy space, it faces numerous biotech and pharmaceutical companies developing immunomodulatory treatments for inflammation and organ injury. Its licensed tissue establishment status in Europe is a regulatory advantage.

More companies in Cell & Gene Therapy →More companies in Europe - Other →